<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00404378</url>
  </required_header>
  <id_info>
    <org_study_id>NKV105093</org_study_id>
    <nct_id>NCT00404378</nct_id>
  </id_info>
  <brief_title>Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant [GW679769]</brief_title>
  <official_title>An Open-label, Two Period, Fixed Sequence Study of Healthy Subjects to Assess the Effect of Repeat Oral Dosing of Ketoconazole on the Pharmacokinetics of a Single Oral Dose of [GW679769]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a two period study of healthy adult subjects to characterize the effect of the dosing
      of ketoconazole on the the way the body reacts to a dose of GW679769, and to assess the
      safety profile of oral casopitant with and without ketoconazole. This study will consist of a
      screening period, two treatment periods and a post-treatment follow-up visit.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 20, 2006</start_date>
  <completion_date type="Actual">January 5, 2007</completion_date>
  <primary_completion_date type="Actual">January 5, 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma levels will be measured for casopitant at Period 1: Day 1, 2 &amp; 3.</measure>
    <time_frame>Period 1: Day 1, 2 &amp; 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma levels will be measured for casopitant and ketoconazole at Period 2: Day 4, 5, 6, 7, &amp; 8.</measure>
    <time_frame>Period 2: Day 4, 5, 6, 7, &amp; 8.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical lab tests monitoring of International Normalized Ratio (INR) adverse events vital signs 12 lead ECGs liver function tests</measure>
    <time_frame>throughout the study</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Nausea and Vomiting, Chemotherapy-Induced</condition>
  <arm_group>
    <arm_group_label>Cohort 1 Treatment Period 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive single oral dose of 100 milligram (mg) of Casopitant. There will be wash out period of 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 Treatment Period 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive ketoconazole 400 mg once daily on Days 1 - 7. On Day 4 subjects will receive a single dose of oral casopitant 100 mg along with ketoconazole.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Treatment Period 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive single oral dose of 50 mg of Casopitant. There will be wash out period of 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Treatment Period 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive ketoconazole 400 mg once daily on Days 1 - 7. On Day 4 subjects will receive a single dose of oral casopitant 50 mg along with ketoconazole.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketoconazole</intervention_name>
    <description>Ketoconazole tablets will be available with dose strength of 200 mg. The dose of ketoconazole 400 mg will be comprised of two 200 mg tablets. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time.</description>
    <arm_group_label>Cohort 1 Treatment Period 2</arm_group_label>
    <arm_group_label>Cohort 2 Treatment Period 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>casopitant 100 mg</intervention_name>
    <description>Casopitant tablets will be available with dose strength of 50 mg. Subjects will receive two 50 mg tablets for the dose of 100 mg. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time</description>
    <arm_group_label>Cohort 1 Treatment Period 1</arm_group_label>
    <arm_group_label>Cohort 1 Treatment Period 2</arm_group_label>
    <other_name>casopitant</other_name>
    <other_name>ketoconazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Casopitant 50 mg</intervention_name>
    <description>Casopitant tablets will be available with dose strength of 50 mg and will receive single dose. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time.</description>
    <arm_group_label>Cohort 2 Treatment Period 1</arm_group_label>
    <arm_group_label>Cohort 2 Treatment Period 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or females

          -  Females must be of non-childbearing potential

          -  Adequate organ functions

          -  Able to swallow and retain oral medications

          -  Able to understand and comply with study requirements

          -  Signed ICF

        Exclusion Criteria:

          -  Clinically relevant abnormality identified on the screening exam or any other medical
             condition or circumstance making the subject unsuitable for participation in the
             study.

          -  History of drug or other allergy which contraindicates participation.

          -  Known immediate hypersensitivity reaction or idiosyncrasy to GW679769 or ketoconazole
             or drugs chemically related to the study medications.

          -  Use of an investigational drug within 28 days preceding the first dose of GW679769 or
             ketoconazole or participation in another clinical trial within the past 30 days.

          -  Blood donation in excess of 1 pint within 56 days prior to first dose of study
             medication or intends to donate within 30 days of the post-treatment follow-up visit.

          -  History of or suspected iron deficiency.

          -  Positive stool for occult blood.

          -  Pepsinogen level below the lower limit of laboratory reference range (LLRR).

          -  Troponin level above 10% of the coefficient of variation of the assay as determined by
             the laboratory performing the test.

          -  For male subjects, any history of hypogonadism and treatments associated with
             hypogonadism including radiation therapy to the testicles.

          -  For female subjects, a positive serum ÃŸ-hCG (beta-human chorionic gonadotropin)
             pregnancy test.

          -  Female subject who is lactating.

          -  Positive urine drug screen (UDS) including alcohol.

          -  Positive for HIV antibody, hepatitis C antibody or hepatitis B surface antigen

          -  Positive urinary cotinine. Subjects must not have used any nicotine-containing
             products, including nicotine patches or gum, within the past 6 months.

          -  Smoking history = 4 packs per day/year or smoked within the past 12 months.

          -  History of drug abuse or dependence within the past 6 months.

          -  History of alcohol abuse within the past 6 months or alcohol consumption in the past 6
             months exceeding study requirements

          -  Presence of uncontrolled nausea &amp; vomiting.

          -  Presence of an active infection.

          -  Any degree of heart failure as defined by the New York Heart Association functional
             classification system.

          -  Active peptic ulcer disease (PUD) or a history of PUD of unknown etiology.

          -  Use of any prescription or non-prescription drug(s), herbal or dietary supplements or
             vitamins within 14 days prior to the first dose of study medication.

          -  Consumption of any food or drink containing grapefruit or grapefruit juice, apple
             juice, Seville oranges, kumquats, pomelos or vegetables from the mustard green family
             (e.g., kale, broccoli, watercress, collard greens, kohlrabi and brussels sprouts,
             mustard) within 14 days prior to the first dose of study medication.

          -  History of cholecystectomy or biliary tract disease.

          -  Any serious or unstable pre-existing medical, psychiatric, or other conditions that
             could interfere with subject's safety, obtaining informed consent or compliance to the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.gsk-clinicalstudyregister.com/study/NKV105093?search=study&amp;search_terms=NKV105093#rs</url>
    <description>Results for study NKV105093 can be found on the GSK Clinical Study Register.</description>
  </link>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2006</study_first_submitted>
  <study_first_submitted_qc>November 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2006</study_first_posted>
  <last_update_submitted>September 11, 2017</last_update_submitted>
  <last_update_submitted_qc>September 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy subjects</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Drug interaction</keyword>
  <keyword>Ketoconazole</keyword>
  <keyword>Casopitant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoconazole</mesh_term>
    <mesh_term>Casopitant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>NKV105093</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>NKV105093</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>NKV105093</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>NKV105093</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>NKV105093</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>NKV105093</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>NKV105093</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

